Fresh news from the ADA (American Diabetes Association):
Takeda’s alogliptin shows impressive results – Takeda Pharmaceutical Co Ltd’s experimental diabetes drug alogliptin significantly lowers blood sugar alone and in combination with other common therapies, according to research presented on Saturday…more More detailed data here.
Sanofi’s experimental injectable diabetes drug shows promise – An experimental injectable type 2 diabetes drug being developed by Sanofi-Aventis SA was well tolerated and significantly improved blood sugar control compared with a placebo, according to data presented on Saturday…more
Head-to-head study of Byetta with an experimental Novo drug…very interesting – Novo Nordisk’s experimental type 2 diabetes drug, liraglutide, was superior in controlling blood sugar in a clinical trial to Eli Lilly and Co and Amylin Pharmaceuticals Inc’s Byetta, the Danish company said on Friday…more
Forbes.com has a bunch of follow-up articles growing out of the recent ASCO meeting:
:: Cancer Revolution, or Me-too Mess? Over the next decade, drug companies could either start selling more cancer drugs than at any time in history or face the biggest string of clinical failures ever…more
:: Cancer Drug Winners and Losers – The data presented at ASCO can have a huge impact both on the share prices of drug firms and on the long-term sales of their medicines. Here’s a roundup of the most important drug studies from the meeting and a look at how they will affect the companies involved…more
:: Novartis Steals the Show – Novartis is emerging as the surprise winner at this year’s annual meeting of the American Society of Clinical Oncology, the year’s biggest cancer conference…more
:: Can Cancer Cure Pfizer? – The recovery of Pfizer, the world’s biggest pharmaceutical company, rests largely on how well Nicholson, 53, can get cancer-fighting drugs out of its research labs and into doctors’ offices…more
:: And, if you want the real short-form bullet-point summary, here’s the high-level ASCO overview from Pharma Exec.
In other news….
Crestor Gaining Market Share – AstraZeneca Plc’s cholesterol drug Crestor is gaining market share in the highly competitive U.S. market, following recent encouraging data and problems faced by rival medicine Vytorin…more
Arthritis Drugs Cause Concern – The U.S. Food and Drug Administration warned American consumers on Wednesday that it is looking into side effects of a class of arthritis drugs that could cause cancer in children…more
Novartis Buying into Antibiotics – Novartis said it’s going to pay $100 million up front, plus as much as $300 million more, for Protez Pharmaceuticals. Protez makes PZ-601, an antibiotic in Phase II development against potentially fatal drug-resistant infections, including the MRSA and ESBL strains…more
Actelion: Who’s circling? -Big drugmakers want to do a deal with Switzerland’s Actelion Ltd — the question is will it be a $1 billion-plus drug marketing alliance or a $7 billion-plus takeover?…more (hat tip: Pharmagossip)
Sexual Harassment and Drug Reps: Watch your Steps, Folks: (from PharmaGossip) Workers at pharmaceutical giant Eli Lilly may want to lay off the Cialis – a longtime saleswoman says she was canned after complaining about her boss’ sexist rants and the come-ons of her sales partner…more
Velcade: a cancer treatment with some potential for lupus? – Velcade, a drug used to treat cancer, might also work against the chronic autoimmune disease lupus, German researchers said on Sunday…more
And…here’s the weekly blog/news summary from Chris Truelove at PharmaLive.